Reporter brief
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents
What happened
Trial registry update: ENROLLING_BY_INVITATION. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The study abstract does not report actual findings, sample size, or effect sizes, making it impossible to determine whether senolytic agents had any benefit on frailty or other outcomes.
- Without reported results, this cannot demonstrate whether senolytic treatment is effective, ineffective, or harmful in the CKD population.
- The design as a trial establishes it could in principle test causation, but the absence of outcome data means no causal claim can be evaluated.
Study design and sample
Rct; Human.
Patients with chronic kidney disease (CKD)
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- May 19, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.